{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:06:19Z","timestamp":1790816779631,"version":"4.1.0"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.toxrep.2025.102021","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T17:04:29Z","timestamp":1744045469000},"page":"102021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Dermatologic toxicities related to cancer immunotherapy"],"prefix":"10.1016","volume":"14","author":[{"given":"Yosra","family":"Vaez-Gharamaleki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Akbarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Jadidi-Niaragh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ata","family":"Mahmoodpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarvin","family":"Sanaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2765-5018","authenticated-orcid":false,"given":"Mohammad-Salar","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.toxrep.2025.102021_bib1","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.1158\/1078-0432.CCR-19-2300","article-title":"Integrating immunotherapy and targeted therapy in cancer treatment: mechanistic insights and clinical implications","volume":"26","author":"Bergholz","year":"2020","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"6","key":"10.1016\/j.toxrep.2025.102021_bib2","first-page":"451","article-title":"Immune checkpoint inhibitors: breakthroughs in cancer treatment","volume":"21","author":"Kong","year":"2024","journal-title":"Cancer Biol. Med."},{"issue":"11","key":"10.1016\/j.toxrep.2025.102021_bib3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.toxrep.2025.102021_bib5","first-page":"6119","article-title":"Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors","volume":"28","author":"Choi","year":"2020","journal-title":"Support. Care Cancer: Off. J. Multinatl. Assoc. Support. Care Cancer"},{"issue":"8","key":"10.1016\/j.toxrep.2025.102021_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255716","article-title":"Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis","volume":"16","author":"Mineiro Dos Santos Garrett","year":"2021","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41698-021-00223-x","article-title":"Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types","volume":"5","author":"Wang","year":"2021","journal-title":"npj Precis. Oncol."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12865-024-00599-y","article-title":"Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors","volume":"25","author":"Wang","year":"2024","journal-title":"BMC Immunol."},{"issue":"5Part A","key":"10.1016\/j.toxrep.2025.102021_bib9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ijwd.2021.10.005","article-title":"Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management","volume":"7","author":"Apalla","year":"2021","journal-title":"Int. J. Women'S. Dermatol."},{"issue":"2","key":"10.1016\/j.toxrep.2025.102021_bib10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3390\/curroncol31020083","article-title":"Vitiligo-like Lesions as a Predictor of Response to Immunotherapy in Non-Small Cell Lung Cancer: Comprehensive Review and Case Series from a University Center","volume":"31","author":"Coelho","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.toxrep.2025.102021_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.glmedi.2023.100046","article-title":"Formulating research questions for evidence-based studies","volume":"2","author":"Hosseini","year":"2024","journal-title":"J. Med., Surg., Public Health"},{"issue":"8","key":"10.1016\/j.toxrep.2025.102021_bib12","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/jid.2015.130","article-title":"Self-Antigen Presentation by Keratinocytes in the Inflamed Adult Skin Modulates T-Cell Auto-Reactivity","volume":"135","author":"Meister","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.toxrep.2025.102021_bib13","article-title":"The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy","volume":"12","author":"Lee","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.toxrep.2025.102021_bib14","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.3389\/fimmu.2019.02254","article-title":"Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells","volume":"10","author":"Anderson","year":"2019","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.toxrep.2025.102021_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.pccm.2023.08.002","article-title":"Li. Pathogenesis, pathological characteristics and individualized therapy for immune-related adverse effects","volume":"1","author":"Miao","year":"2023","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13046-020-01749-x","article-title":"The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors","volume":"39","author":"Jia","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.toxrep.2025.102021_bib17","first-page":"3111","article-title":"IFN\u2011\u03b3 induces apoptosis in human melanocytes by activating the JAK1\/STAT1 signaling pathway","volume":"22","author":"Su","year":"2020","journal-title":"Mol. Med. Rep."},{"issue":"2","key":"10.1016\/j.toxrep.2025.102021_bib18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","article-title":"Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatol. Ther."},{"issue":"6","key":"10.1016\/j.toxrep.2025.102021_bib19","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J. Immunol. (Baltim., Md: 1950)"},{"issue":"3, Part B","key":"10.1016\/j.toxrep.2025.102021_bib20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2021.06.040","article-title":"Immune Checkpoint Blockade and Skin Toxicity Pathogenesis","volume":"142","author":"Ma","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.toxrep.2025.102021_bib21","doi-asserted-by":"crossref","first-page":"1071983","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Yukie. Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.toxrep.2025.102021_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/antib11030044","article-title":"Deciphering the contribution of BP230 autoantibodies in bullous pemphigoid","volume":"11","author":"Cole","year":"2022","journal-title":"Antibodies"},{"key":"10.1016\/j.toxrep.2025.102021_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40744-018-0100-z","article-title":"Role of human leukocyte antigens (HLA) in autoimmune diseases","volume":"5","author":"Bodis","year":"2018","journal-title":"Rheumatol. Ther."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.toxrep.2025.102021_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.924849","article-title":"Skin Microbiome and Treatment-Related Skin Toxicities in Patients With Cancer: A Mini-Review","volume":"12","author":"Richardson","year":"2022","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.toxrep.2025.102021_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14122995","article-title":"Contribution of the Skin-Gut Axis to Immune-Related Adverse Events with Multi-System Involvement","volume":"14","author":"Kuo","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"ement_1","key":"10.1016\/j.toxrep.2025.102021_bib27","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/bjd\/ljad257","article-title":"How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach","volume":"189","author":"Kawsar","year":"2023","journal-title":"Br. J. Dermatol."},{"issue":"40","key":"10.1016\/j.toxrep.2025.102021_bib28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/EDBK_289911","article-title":"Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy","author":"Deutsch","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu. Meet."},{"issue":"5","key":"10.1016\/j.toxrep.2025.102021_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2023.100190","article-title":"Skin Infiltrate Composition as a Telling Measure of Responses to Checkpoint Inhibitors","volume":"3","author":"Kosche","year":"2023","journal-title":"JID Innov."},{"issue":"7","key":"10.1016\/j.toxrep.2025.102021_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15072084","article-title":"Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma","volume":"15","author":"Nikolaou","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.toxrep.2025.102021_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.1889449","article-title":"\"Skin rashes\" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management","volume":"18","author":"Sollena","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"issue":"2","key":"10.1016\/j.toxrep.2025.102021_bib32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jamadermatol.2018.4560","article-title":"Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics","volume":"155","author":"Phillips","year":"2019","journal-title":"JAMA Dermatol."},{"issue":"11","key":"10.1016\/j.toxrep.2025.102021_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007530","article-title":"New perspectives in cancer immunotherapy: targeting IL-6 cytokine family","volume":"11","author":"Soler","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.toxrep.2025.102021_bib34","doi-asserted-by":"crossref","first-page":"684","DOI":"10.18632\/oncotarget.323","article-title":"New perspectives on the role of vitiligo in immune responses to melanoma","volume":"2","author":"Byrne","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.toxrep.2025.102021_bib35","article-title":"The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.toxrep.2025.102021_bib36","article-title":"Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice","volume":"60","author":"Popa","year":"2024","journal-title":"Med. (Kaunas., Lith. )"},{"issue":"6","key":"10.1016\/j.toxrep.2025.102021_bib37","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2326-6066.CIR-18-0682","article-title":"IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy","volume":"7","author":"Johnson","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"8","key":"10.1016\/j.toxrep.2025.102021_bib38","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review","volume":"158","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol."},{"issue":"17","key":"10.1016\/j.toxrep.2025.102021_bib39","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3390\/diagnostics14171958","article-title":"A Case of Bullous Pemphigoid with Significant Infiltration of CD4-Positive T Cells during Treatment with Pembrolizumab, Accompanied by Pembrolizumab-Induced Multi-Organ Dysfunction","volume":"14","author":"Mima","year":"2024","journal-title":"Diagnostics"},{"issue":"2","key":"10.1016\/j.toxrep.2025.102021_bib40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/1346-8138.16654","article-title":"What's new in the pathogeneses and triggering factors of bullous pemphigoid","volume":"50","author":"Ujiie","year":"2023","journal-title":"J. Dermatol."},{"issue":"2","key":"10.1016\/j.toxrep.2025.102021_bib41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/biomedicines11020323","article-title":"A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy","volume":"11","author":"Parisi","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.toxrep.2025.102021_bib42","article-title":"A Case of Stevens-Johnson Syndrome\/toxic epidermal necrolysis in a patient receiving chemo-immunotherapy with pemetrexed and pembrolizumab","volume":"3","author":"Storandt","year":"2021","journal-title":"Curr. Probl. Cancer.: Case Rep."},{"key":"10.1016\/j.toxrep.2025.102021_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2023.1147513","article-title":"Mucocutaneous adverse events to immune checkpoint inhibitors","volume":"4","author":"Muhaj","year":"2023","journal-title":"Front. Allergy"},{"issue":"6(6","key":"10.1016\/j.toxrep.2025.102021_bib44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/jdv.18200","article-title":"Anticancer treatments and photosensitivity","volume":"36","author":"Sibaud","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol.: JEADV"},{"issue":"4","key":"10.1016\/j.toxrep.2025.102021_bib45","first-page":"304","article-title":"Nivolumab-induced eosinophilic fasciitis: An unusual immune-related adverse event that needs to be recognized by practitioners","volume":"150","author":"Benzaquen","year":"2023","journal-title":"Ann. De. Dermatol. Et. De. V. \u00e9N.\u00e9R. \u00e9ologie"},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib46","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/annrheumdis-2022-eular.3118","article-title":"POS0889\u2005Case Series of Patients with Eosinophilic Fasciitis Secondary to Immune Checkpoint Inhibitors Therapy","volume":"81","author":"Huang","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.toxrep.2025.102021_bib47","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.toxrep.2025.102021_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13074","article-title":"Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review","volume":"32","author":"Ravi","year":"2019","journal-title":"Dermatol. Ther."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib49","first-page":"123","article-title":"Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist","volume":"93","author":"Tattersall","year":"2020","journal-title":"Yale J. Biol. Med."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib50","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1186\/s40001-024-02167-x","article-title":"Cancer treatment-related xerostomia: basics, therapeutics, and future perspectives","volume":"29","author":"Hosseini","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.toxrep.2025.102021_bib51","article-title":"Oral and cutaneous immune-related adverse events in cancer patients: Prevalence and overall survival","author":"de Oliveira Filho","year":"2024","journal-title":"Oral. Dis."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"issue":"6","key":"10.1016\/j.toxrep.2025.102021_bib53","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/bjd.15237","article-title":"Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors","volume":"176","author":"Zarbo","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.toxrep.2025.102021_bib54","unstructured":"U.S Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 2017 [Available from: \u3008https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_8.5x11.pdf\u3009."},{"issue":"6","key":"10.1016\/j.toxrep.2025.102021_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.toxrep.2025.102021_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.toxrep.2025.102021_bib57","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaad.2022.12.048","article-title":"Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study","volume":"88","author":"Zhang","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.toxrep.2025.102021_bib58","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/cancers16020340","article-title":"Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis","volume":"16","author":"Curkovic","year":"2024","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.toxrep.2025.102021_bib59","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaad.2024.07.1463","article-title":"Antibody-drug conjugates: A review of cutaneous adverse effects","volume":"91","author":"Saberi","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.toxrep.2025.102021_bib60","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"issue":"2","key":"10.1016\/j.toxrep.2025.102021_bib61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr. Probl. Cancer"},{"issue":"3","key":"10.1016\/j.toxrep.2025.102021_bib62","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2021.03.094","article-title":"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis","volume":"86","author":"Wongvibulsin","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"issue":"8","key":"10.1016\/j.toxrep.2025.102021_bib63","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14740338.2021.1915279","article-title":"Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion","volume":"20","author":"Lommerts","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"issue":"7","key":"10.1016\/j.toxrep.2025.102021_bib64","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib65","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"7","key":"10.1016\/j.toxrep.2025.102021_bib66","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/cancers16071440","article-title":"Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations","volume":"16","author":"Casagrande","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.toxrep.2025.102021_bib67","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib68","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40364-021-00314-8","article-title":"Risk factors for immune-related adverse events: what have we learned and what lies ahead?","volume":"9","author":"Liu","year":"2021","journal-title":"Biomark. Res."},{"issue":"4","key":"10.1016\/j.toxrep.2025.102021_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007675","article-title":"Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy","volume":"12","author":"Chen","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"17","key":"10.1016\/j.toxrep.2025.102021_bib70","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.toxrep.2025.102021_bib71","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1074\/jbc.M606262200","article-title":"Novel Genomic Effects of Glucocorticoids in Epidermal Keratinocytes: INHIBITION OF APOPTOSIS, INTERFERON-\u03b3 PATHWAY, AND WOUND HEALING ALONG WITH PROMOTION OF TERMINAL DIFFERENTIATION*","volume":"282","author":"Stojadinovic","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.toxrep.2025.102021_bib72","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.3390\/curroncol29040234","article-title":"Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article","volume":"29","author":"Chen","year":"2022","journal-title":"Curr. Oncol. (Tor., Ont. )"},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib73","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management","volume":"25","author":"Muntyanu","year":"2021","journal-title":"J. Cutan. Med. Surg."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib74","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-3083.2011.04185.x","article-title":"Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses","volume":"26","author":"Zuberbier","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"22","key":"10.1016\/j.toxrep.2025.102021_bib75","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1002\/cncr.34474","article-title":"Comparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: A randomized phase 2 clinical trial","volume":"128","author":"Zhou","year":"2022","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.toxrep.2025.102021_bib76","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.det.2018.02.010","article-title":"Pruritus Associated with Targeted Anticancer Therapies and Their Management","volume":"36","author":"Wu","year":"2018","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.toxrep.2025.102021_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114172","article-title":"Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma","volume":"207","author":"Verheijden","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.toxrep.2025.102021_bib78","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib79","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.toxrep.2025.102021_bib80","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/09546634.2019.1589643","article-title":"Biologics for chronic inflammatory skin diseases: An update for the clinician","volume":"31","author":"Yao","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.toxrep.2025.102021_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.898790","article-title":"High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer","volume":"9","author":"Kuo","year":"2022","journal-title":"Front. Med."},{"issue":"12","key":"10.1016\/j.toxrep.2025.102021_bib82","first-page":"672","article-title":"The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus","volume":"31","author":"Dreno","year":"2023","journal-title":"Support. Care Cancer: Off. J. Multinatl. Assoc. Support. Care Cancer"},{"key":"10.1016\/j.toxrep.2025.102021_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103376","article-title":"Cutaneous adverse events associated with immune checkpoint blockade: a systematic review and meta-analysis","volume":"163","author":"Han","year":"2021","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib84","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/bjd\/ljae053","article-title":"Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study","volume":"191","author":"Wan","year":"2024","journal-title":"Br. J. Dermatol."},{"issue":"9","key":"10.1016\/j.toxrep.2025.102021_bib85","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/jdv.16311","article-title":"Cutaneous adverse events: a predictor of tumour response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients","volume":"34","author":"Bottlaender","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib86","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaad.2024.03.029","article-title":"Dermatologic toxicity associated with targeted and immunotherapies in stage-IV non-small cell lung cancer patients: A 14-year cohort","volume":"91","author":"Peng","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib87","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jdermsci.2017.10.009","article-title":"Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients","volume":"89","author":"Fujisawa","year":"2018","journal-title":"J. Dermatol. Sci."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib88","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/cei\/uxab002","article-title":"Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors","volume":"207","author":"Faraj","year":"2022","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.toxrep.2025.102021_bib89","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1046\/j.1523-1747.2001.01408.x","article-title":"Specific Cytotoxic T Lymphocyte Responses Against Melan-A\/MART1, Tyrosinase and Gp100 in Vitiligo by the Use of Major Histocompatibility Complex\/Peptide Tetramers: the Role of Cellular Immunity in the Etiopathogenesis of Vitiligo","volume":"117","author":"Palermo","year":"2001","journal-title":"J. Invest. Dermatol."},{"issue":"12","key":"10.1016\/j.toxrep.2025.102021_bib90","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/2326-6066.CIR-18-0487","article-title":"The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy","volume":"6","author":"Young","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"11","key":"10.1016\/j.toxrep.2025.102021_bib91","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma","volume":"63","author":"Del Castillo","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.toxrep.2025.102021_bib92","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.toxrep.2025.102021_bib93","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3390\/cancers15051629","article-title":"Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events","volume":"15","author":"Les","year":"2023","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.toxrep.2025.102021_bib94","doi-asserted-by":"crossref","DOI":"10.1200\/PO.24.00139","article-title":"Efficacy and Safety of Immune Checkpoint Blockade in Patients With Li-Fraumeni Syndrome","author":"Bottosso","year":"2024","journal-title":"JCO Precis. Oncol."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib95","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s12672-024-01435-w","article-title":"Current insights and future directions of Li-Fraumeni syndrome","volume":"15","author":"Hosseini","year":"2024","journal-title":"Discov. Oncol."},{"issue":"6","key":"10.1016\/j.toxrep.2025.102021_bib96","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.anai.2021.02.009","article-title":"Immune-related cutaneous adverse events due to checkpoint inhibitors","volume":"126","author":"Wang","year":"2021","journal-title":"Ann. Allergy, Asthma Immunol.: Off. Publ. Am. Coll. Allergy, Asthma, Immunol."},{"key":"10.1016\/j.toxrep.2025.102021_bib97","article-title":"Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction","volume":"14","author":"Cao","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.toxrep.2025.102021_bib98","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1613","article-title":"Immune-related adverse events in non-small cell lung cancer: Occurrence, mechanisms and therapeutic strategies","volume":"14","author":"Lin","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.toxrep.2025.102021_bib99","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejca.2021.08.031","article-title":"Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy","volume":"157","author":"Dimitriou","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.toxrep.2025.102021_bib100","doi-asserted-by":"crossref","first-page":"6805","DOI":"10.3390\/curroncol30070498","article-title":"Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors","volume":"30","author":"Teng","year":"2023","journal-title":"Curr. Oncol. (Tor., Ont. )"},{"issue":"3","key":"10.1016\/j.toxrep.2025.102021_bib101","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjd.12389","article-title":"HLA-B*\u200958: 01 is a risk factor for allopurinol-induced DRESS and Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in a Portuguese population","volume":"169","author":"Gon\u00e7alo","year":"2013","journal-title":"Br. J. Dermatol."},{"issue":"11","key":"10.1016\/j.toxrep.2025.102021_bib102","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/all.13821","article-title":"HLA-B*\u200957:01 confers genetic susceptibility to carbamazepine-induced SJS\/TEN in Europeans","volume":"74","author":"Mockenhaupt","year":"2019","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib103","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40164-023-00442-x","article-title":"Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target","volume":"12","author":"Zhang","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.toxrep.2025.102021_bib104","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jare.2023.11.027","article-title":"The role of gut microbiota and metabolites in cancer chemotherapy","volume":"64","author":"Li","year":"2024","journal-title":"J. Adv. Res."},{"issue":"12","key":"10.1016\/j.toxrep.2025.102021_bib105","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.21037\/atm-20-6427","article-title":"The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer","volume":"9","author":"Naqash","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib106","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/eji.201444972","article-title":"The role of the microbiota in inflammation, carcinogenesis, and cancer therapy","volume":"45","author":"Dzutsev","year":"2015","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.toxrep.2025.102021_bib107","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","article-title":"Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1","volume":"28","author":"McCulloch","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.toxrep.2025.102021_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115221","article-title":"Gut microbiome and immune checkpoint inhibitor toxicity","volume":"216","author":"Verheijden","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.toxrep.2025.102021_bib109","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fimmu.2021.756872","article-title":"Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.toxrep.2025.102021_bib110","article-title":"Modulating the gut microbiota by probiotics, prebiotics, postbiotics, and fecal microbiota transplantation: An emerging trend in cancer patient care","volume":"1878","author":"Ciernikova","year":"2023","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Rev. Cancer"},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib111","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13073-024-01285-9","article-title":"Gut microbiome for predicting immune checkpoint blockade-associated adverse events","volume":"16","author":"Hu","year":"2024","journal-title":"Genome Med."},{"key":"10.1016\/j.toxrep.2025.102021_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2025.02.044","article-title":"Skin Microbiome, Inflammation, and Skin Toxicities in Women with Breast Cancer Receiving Moderately Hypofractionated Radiation Therapy","author":"Bai","year":"2025","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib113","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1038\/s41467-024-47072-3","article-title":"Dermal injury drives a skin to gut axis that disrupts the intestinal microbiome and intestinal immune homeostasis in mice","volume":"15","author":"Dokoshi","year":"2024","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.toxrep.2025.102021_bib114","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","article-title":"Interaction between microbiota and immunity in health and disease","volume":"30","author":"Zheng","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.toxrep.2025.102021_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114985","article-title":"Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review","volume":"164","author":"Zhao","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.toxrep.2025.102021_bib116","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.230014","article-title":"Short chain fatty acids: key regulators of the local and systemic immune response in inflammatory diseases and infections","volume":"13","author":"Ney","year":"2023","journal-title":"Open Biol."},{"issue":"4","key":"10.1016\/j.toxrep.2025.102021_bib117","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.3390\/ijms24043494","article-title":"Bacterial metabolites: a link between gut microbiota and dermatological diseases","volume":"24","author":"Stec Albert","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib118","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib119","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","article-title":"Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia","volume":"16","author":"Tan","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.toxrep.2025.102021_bib120","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jaad.2023.10.065","article-title":"Cutaneous immune-related adverse event burden and effect on immunotherapy: A retrospective review of the experience at a tertiary care immunotherapy center","volume":"90","author":"Le","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"issue":"9","key":"10.1016\/j.toxrep.2025.102021_bib121","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/ced\/llae060","article-title":"Cutaneous immune-related adverse events: incidence rates, risk factors and association with extracutaneous toxicity \u2013 a prospective study of 189 patients treated with checkpoint inhibitors at a Spanish tertiary care hospital","volume":"49","author":"Juan-Carpena","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"issue":"8","key":"10.1016\/j.toxrep.2025.102021_bib122","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.toxrep.2025.102021_bib123","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jaad.2019.11.017","article-title":"Vitiligo under anti\u2013programmed cell death-1 therapy is associated with increased survival in melanoma patients","volume":"82","author":"Nardin","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.toxrep.2025.102021_bib124","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study","volume":"79","author":"Lee","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.toxrep.2025.102021_bib125","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jaad.2019.12.068","article-title":"Bullous pemphigoid after anti\u2013programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes","volume":"87","author":"Nelson","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.toxrep.2025.102021_bib126","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1016\/j.clml.2019.12.014","article-title":"Immune-related Adverse Events Associated With Checkpoint Inhibition in the Setting of CAR T Cell Therapy: A Case Series","volume":"20","author":"Thiruvengadam","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"10.1016\/j.toxrep.2025.102021_bib127","doi-asserted-by":"crossref","DOI":"10.1097\/CJI.0000000000000127","article-title":"Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients","volume":"39","author":"Boudewijns","year":"2016","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.toxrep.2025.102021_bib128","first-page":"57","article-title":"Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases","volume":"25","author":"Kazumi","year":"2011","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.toxrep.2025.102021_bib129","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1634\/theoncologist.2019-0508","article-title":"Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature","volume":"25","author":"Chan","year":"2020","journal-title":"oncologist"},{"issue":"6","key":"10.1016\/j.toxrep.2025.102021_bib130","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/CMR.0000000000000017","article-title":"Sweet\u2019s syndrome in a patient with metastatic melanoma after ipilimumab therapy","volume":"23","author":"Pintova","year":"2013","journal-title":"Melanoma Res."},{"key":"10.1016\/j.toxrep.2025.102021_bib131","doi-asserted-by":"crossref","unstructured":"Moehler M., Heo J., Lee H.C., Tak W.Y., Chao Y., Paik S.W., et al. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in p atients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). OncoImmunology.8(8).DOI:10.1080\/2162402x.2019.1615817.","DOI":"10.1080\/2162402X.2019.1615817"},{"issue":"17","key":"10.1016\/j.toxrep.2025.102021_bib132","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.toxrep.2025.102021_bib133","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1080\/10428194.2023.2221756","article-title":"Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab","volume":"64","author":"Parisi","year":"2023","journal-title":"Leuk. Lymphoma"}],"container-title":["Toxicology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750025001398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750025001398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T14:58:52Z","timestamp":1762613932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214750025001398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":133,"alternative-id":["S2214750025001398"],"URL":"https:\/\/doi.org\/10.1016\/j.toxrep.2025.102021","relation":{},"ISSN":["2214-7500"],"issn-type":[{"value":"2214-7500","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatologic toxicities related to cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Toxicology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxrep.2025.102021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102021"}}